Hormone therapy, family history, and ER-positive breast cancer — what the WHI data tell us

One of the most common questions I hear from women in clinic is: “If breast cancer runs in my family, is hormone therapy (HT) especially risky for me?” A clear, patient-facing way into that question is the 2009 follow-up analysis of Women’s Health Initiative (WHI) trial data by Gramling and colleagues — available on PubMed/PMC — which directly tested whether a first-degree family history of breast cancer magnifies the breast-cancer risk from combined estrogen-plus-progestin therapy. PubMed

Quick takeaways (easy to remember)

• In the WHI randomized trial, combined estrogen + synthetic progestin (E+P) increased the risk of invasive breast cancer overall.

• Family history (first-degree relative) and E+P each increased breast-cancer risk, but they acted independently — there was no meaningful interaction. In other words, having a first-degree family history did not amplify the additional risk from E+P beyond the risk you’d expect from each factor alone. PubMed

• The same lack of interaction held when the authors limited the analysis to estrogen-receptor positive (ER+) invasive breast cancers. PubMed

  
  

What the study actually did (brief methods)

Gramling et al. followed 16,608 postmenopausal women from the WHI randomized trial (E+P vs placebo) for an average of ~5.6 years. During follow-up there were 349 invasive breast cancer cases. They calculated the risk difference attributable to hormone therapy among women with and without a first-degree family history and then tested whether the two risks interacted (i.e., whether the combined effect was more than additive). The interaction contrast was essentially zero — statistically negligible — for overall invasive cancer and for ER-positive cancers. PubMed

What that means for women with family history of ER+ breast cancer

• Family history still matters. A first-degree relative with breast cancer raises a woman’s baseline lifetime risk relative to someone without that history (this is well established from genetic and epidemiologic studies). The WHI analysis does not negate that baseline increased risk.

• But HT doesn’t appear to disproportionately multiply that baseline risk. According to this WHI analysis, the extra invasive-breast-cancer risk associated with combined E+P was similar in women with and without a first-degree family history. Simply put: the added risk from combined HT was not significantly larger for women who reported a first-degree family history.

  
  

Important context & caveats

1. WHI used one regimen (conjugated equine estrogen + medroxyprogesterone acetate). Results may not translate exactly to other estrogen formulations, to transdermal routes, or to bioidentical regimens. Later work and meta-analyses show that risk can vary by type of HT and by duration of use. Breast Cancer Research Foundation

2. Timing and duration matter. Short-term use around menopause appears to carry a smaller absolute increase in risk than long-term use starting at older ages; overall population risk increases with longer duration. Recent modelling suggests that short courses of HRT (e.g., ~5 years around age 50) add only a modest absolute increase in breast-cancer incidence and mortality — even for women with a stronger family history — though longer use raises the absolute excess. Institute of Cancer Research+1

3. Family history ≠ high-penetrance mutation. A family history (one or more affected first-degree relatives) increases baseline risk but is not the same as carrying a BRCA1/2 or other high-penetrance pathogenic variant. WHI’s analysis did not stratify by known genetic mutation carriers; decisions for BRCA carriers or other high-risk genetic profiles should follow specialized oncology/genetics guidance. PubMed

4. Absolute risks vs relative risks. For most women, the absolute increase in breast-cancer cases attributable to several years of HRT is small; the decision should weigh symptom burden and quality-of-life gains (hot-flash control, sleep, bone protection) against that small absolute risk increase. Recent models put the incremental lifetime breast-cancer risk from 5 years of HRT in context to show modest absolute increases even for those with strong family history. Institute of Cancer Research

   
   

Practical clinical messaging you can use

• “Yes, your family history raises your baseline breast-cancer risk — that’s important to factor into screening and prevention. But WHI data show combined hormone therapy does not appear to multiply that risk beyond what each factor contributes independently.” PubMed

• “Decisions about hormone therapy should be individualized: consider your symptom severity, breast-cancer family history (and whether genetic testing changes risk), cardiovascular and clotting risk, and your values about quality of life.”

• “If concerned about breast cancer specifically, discuss options with your clinician — including shorter duration use, different HT formulations/routes, enhanced surveillance, or non-hormonal symptom treatments.” Breast Cancer Research Foundation

  
  

Bottom line

The WHI follow-up analyzed in Gramling et al. (2009) gives reassuring evidence that a first-degree family history of breast cancer does not substantially amplify the additional breast-cancer risk from combined estrogen-plus-progestin therapy, including ER-positive cancers. That finding supports individualized shared decision-making rather than a blanket rule of “no HRT if breast cancer runs in your family.” As always, the nuance matters: type of HT, duration, timing, and specific genetic risk should guide the final plan. PubMed+2Institute of Cancer Research+2